CAMILLE MEYHOFF: Open Payments
NPI 1720187669 · BISMARCK, ND. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$937 in 55 payments from 18 companies in 2025. Trend: 2023 $970 · 2024 $839 · 2025 $937
Food & beverage: $937
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $195 |
| PFIZER INC. | 10 | $168 |
| Actelion Pharmaceuticals US, Inc. | 3 | $71 |
| Amgen Inc. | 4 | $66 |
| Merck Sharp & Dohme LLC | 4 | $60 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| United Therapeutics Corporation | 2 | $44 |
| BridgeBio Pharma, Inc. | 2 | $33 |
| Philips North America LLC | 1 | $33 |
| LeMaitre Vascular, Inc. | 1 | $33 |
Products named: LEQVIO, ELIQUIS, UPTRAVI, REPATHA, VERQUVO, VYNDAQEL, AMVUTTRA, Tyvaso.
Industry payments across ND — which companies pay providers there.
